Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China
Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China
复制标题
DOI：
10.1016/j.jacl.2015.10.009
复制
发表时间：
2016-02-01
影响因子：
4.4
通讯作者：
Ning, Guang
中科院分区：
文献类型：
--
作者：
Yan, Li;Xu, Ming Tong;Ning, Guang
目的：本研究的目的是评估来自中国大城市顶级内分泌诊所的2型糖尿病（T2DM）患者的血脂水平以及对血脂异常的认识、治疗和控制。材料与方法：2010年至2011年，在中国大部分主要城市排名前列的医院的20个内分泌科门诊，对4807名40 - 75岁的中国成年人进行了代表性样本的横断面研究。测量血脂水平，记录和评估血脂异常的治疗情况。结果：在本研究中，T2DM患者的血脂异常患病率为67.1%。血脂异常患者中知晓率为68.7%，知晓率为55.9%。在接受降脂治疗的受试者中，686名受试者低密度脂蛋白胆固醇（LDL-C）控制在2.60 mmol/L以下，比例为39.4%。在既往有心血管疾病的患者中，达到LDL-C目标（1.80纳莫/升）的参与者百分比为15.3%。结论：我国T2DM患者血脂异常患病率较高，对血脂异常的认识、治疗和控制相对较低。这就需要对这些患者血脂异常的认识和干预。(C) 2016年全国血脂协会。版权所有。
OBJECTIVE: The aim of this study was to assess the levels of serum lipid and awareness, treatment, and control of dyslipidemia in type 2 diabetes mellitus (T2DM) patients from top-ranked endocrinology clinics in large cities of China.MATERIALS AND METHODS: A cross-sectional study in a representative sample of 4807 Chinese adults 40 to 75 years of age was conducted during 2010 to 2011 at 20 endocrinology clinics in top ranked hospitals covering most of the major cities of China. Serum lipid levels were measured, and treatment of dyslipidemia was recorded and assessed.RESULTS: In the present study, the prevalence of dyslipidemia was 67.1% in T2DM subjects. Among those with dyslipidemia, the proportion of awareness and treatment was 68.7% and 55.9%. Among participants with lipid-lowering therapy, 686 subjects achieved the low-density lipoprotein cholesterol (LDL-C) control less than 2.60 mmol/L, with the rate being 39.4%. In those patients with previous cardiovascular disease, the percentage of participants who achieved LDL-C goal (1.80 namol/L) was 15.3%.CONCLUSION: The prevalence of dyslipidemia is high, and the awareness, treatment, and control of dyslipidemia are relatively low in Chinese T2DM patients. This calls for the awareness and intervention of dyslipidemia in these patients. (C) 2016 National Lipid Association. All rights reserved.